Role of group IIA phospholipase A2 in rat colitis induced by dextran sulfate sodium

European Journal of Pharmacology

Volumn 472, Issue 1-2, 2003, Pages 147-158

  Tomita, Yasuhiko ^a   Jyoyama, Hirokuni ^a   Kobayashi, Mika ^a   Kuwabara, Kenji ^a   Furue, Shingo ^a   Ueno, Masahiko ^a   Yamada, Katsutoshi ^a   Ono, Takashi ^a   Teshirogi, Isao ^a   Nomura, Kouji ^a   Arita, Hitoshi ^a   Okayasu, Isao ^b   Hori, Yozo ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colitis; Dextran sulfate sodium; Group IIA phospholipase A2; S 3013 LY333013

Indexed keywords

ACETIC ACID DERIVATIVE; DEXTRAN SULFATE; ICOSANOID; ISOENZYME; LY 333013; MYELOPEROXIDASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; S 3013; UNCLASSIFIED DRUG; VARESPLADIB; [METHYL[[3 (AMINOOXOACETYL) 2 ETHYL 1 (PHENYLMETHYL)] 1H INDOL 4 YL]OXY]ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DESCENDING COLON; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME RELEASE; EPITHELIUM; EROSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; LAMINA PROPRIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 12444252938     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01859-4     Document Type: Article

References (34)

1. 2. Annu. Rev. Pharmacol. Toxicol. 39:1999;175-189.
2. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. 37:1959;911-919.
3. 2. J. Biol. Chem. 269:1994;13057-13060.
4. 2: 3. Indole-3-glyoxamides. J. Med. Chem. 39:1996;5159-5175.
5. Elson C.O., Sartor R.B., Tennyson G.S., Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology. 109:1995;1344-1367.
6. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 115:1998;182-205.
7. 2 in oleic acid-induced acute lung injury in rabbits. Am. J. Respir. Crit. Care Med. 160:1999;1292-1302.
8. Gaudio E., Taddei G., Vetuschi A., Sferra R., Frieri G., Ricciardi G., Caprilli R. Dextran sulfate sodium colitis in rats: clinical, structural, and ultrastructural aspects. Dig. Dis. Sci. 44:1999;1458-1475.
9. 2 in intestine in ulcerative colitis. Gut. 40:1997;95-101.
10. 2 mass concentration in serum and colonic mucosa in Crohn's disease. Clin. Chem. Lab. Med. 36:1998;751-755.
11. 2 in protection against mucosal damage. Digestion. 63(Suppl. 1):2001;73-80.
12. Hori Y., Odaguchi K., Jyoyama H., Yasui K., Mizui T. Differential effect of benexate hydrochloride betadex on prostaglandin levels in stomach and inflammatory site in rats. Jpn. J. Pharmacol. 72:1996;183-190.
13. Kabashima K., Saji T., Murata T., Nagamachi N., Matsuoka T., Segi E., Tsubo K., Sugimoto Y., Kobayashi T., Miyachi Y., Ichikawa A., Narumiya S. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109:2002;883-893.
14. Kimura I., Nagahama S., Kawasaki M., Kamiya A., Kataoka M. Study on the experimental ulcerative colitis (UC) model induced by dextran sulfate sodium (DSS) in rats (2). Folia Pharmacol. Jpn. 105:1995;145-152.
15. Kimura I., Kawasaki M., Nagahama S., Matsuda A., Kataoka M., Kokuba Y. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats. Arzneim. Forsch. 48:1998;1091-1096.
16. 2 mediates lung injury in intestinal ischemia-reperfusion. Ann. Surg. 232:2000;90-97.
17. 2 in human platelets. J. Biol. Chem. 268:1993;26796-26804.
18. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 87:1984;1344-1350.
19. 2 acting against Escherichia coli. Infect. Immun. 64:1996;2425-2430.
20. 2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis. Gut. 33:1992;914-921.
21. 2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut. 35:1994;1593-1598.
22. 2 in colonic mucosa of patients with inflammatory bowel disease. Am. J. Gastroenterol. 92:1997;289-292.
23. 2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J. Biol. Chem. 274:1999;3103-3115.
24. 2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett. 273:1990;23-26.
25. 2 in inflammatory diseases and trauma. Biochim. Biophys. Acta. 1488:2000;83-90.
26. 2 in rat ovaries: stimulatory action on progesterone release. Endocrinology. 135:1994;603-609.
27. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 98:1990;694-702.
28. 2-activating protein and by activation of phospholipase C and D. J. Biol. Chem. 276:2001;5467-5475.
29. 2 enzymes: classification and characterization. Biochim. Biophys. Acta. 1488:2000;1-19.
30. 2 inhibitor: a new class of anti-inflammatory drugs, SPI. J. Pharmacol. Exp. Ther. 288:1999;1117-1124.
31. Tessner T.G., Cohn S.M., Schloemann S., Stenson W.F. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology. 115:1998;874-882.
32. 2 isozymes. J. Lipid Res. 34:1993;837-844.
33. 2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediat. 8:1993;1-30.
34. 2. J. Clin. Invest. 97:1996;250-257.